Nootropil, Lucetam, Piracetam

1. Loss of memory, vertigo, lack of concentration or alertness, personal negligence, change of mood, dete­rioration in behaviour. - Tablet **0 mg 3 times/day orally, or tablet ***0 mg 2 times/day, morning and evening for 6 weeks conti­nuously. After improvement of symptom, take capsule **0 mg 3 times/day as the maintenance dose.
Solution *0%-Adults: 5 ml 3 times/day orally.

2 Treatment of alcoholism and withdrawal symptom after stop drinking. - In the initial period: by injection the dose of ***2 g in four divided doses. After improvement of symptom, fol­lowed by dose of 2.4 g/day orally in **3 divided doses before or after meal.

3. Treatment of sickle cell anaemia. - Severe symptoms Infuse *0 mq/kg in **0 ml of glucose solution every 8 hours for 3 days. Maintenance therapy (Adult) by intramuscular injec­tion of 1 g/day continuously for 6 months. After impro­vement of symptom, followed by dose of 1.2 g orally every 8 hours.
(Children) **0 mg 3 times/day orally.

4. Treatment of cognitive deficit as a result of cerebrovascular diseases or head injury. - Initially by infusion or intravenous injection dose of ***2 g/day until recovery. Maintenance therapy: **0 mg 3 times/day orally, or Solution *0% :5 ml 3 times/day orally.

5. Cortical myoclonus, alone or in combination.
Initial dosage: Initial dose is *2g/day, increasing the dose by 4.8 g every **4 days, up to the maximum dose of *4 g/day in two or three sub-doses. In case of a weak or no response, the administration of *4 g/day will be continued until the 7th day. If it becomes active then reducing the dose by 1.2 g every other day until myoclonus appear again to determine the mean active dose. If there is still no response, treatment will be discontinued on the 7th day. Treatment with other, anti-myocfonus drug will be maintained or reduced depending on the obtained clinical benefit. The treat­ment with Nootropil will be maintained as long as the cerebral pathology persists. An attempt to decrease or to discontinue the drug therapy will be made every 6 months. Treatment will be discontinued by reducing the dose of Nootropil by 1.2 g every other day.

6. The administration Nootropil together with improving remedial teaching to treat children with learning difficulties in reading which cannot be explained by intel­lectual backwardness, inadequate education or by family environment.
Children ***3 years old: total dose 3.3 g/day in two sub-doses.
Solution *0%: 8 ml 2times/day. It may be given in fruit juice or in some other drinks. Treatment should be continued throughout the school year.

Drug Class and Mechanism

Nootropil is a ¢€œnootrope ¢€œ that is to say it is a psychotropic agent which acts directly on the brain to improve the efficacy of the telencephalon in both normal subjects and those suffering from some functional deficit. This area of the brain is involved in cognition and also has a role to play in teaming and memory, in alertness and in consciousness. Nootropil does not produce either sedation or stimulation. Nootropil can act on the Central Nervous System in a variety of ways. It will modify neurotransmission within the brain, and can help to improve the metabolic environ­ment essential for good neuronal function. It is also a ha emorrheo logical agent and can improve microcirculation without producing vasodilation. When given as acute or long term treatment for patients suffering from a tunctional CNS deficit, or after cerebral trauma such as hypoxia or intoxi­cation, and after electroshock therapy, it will heighten alertness and increase cognitive function. These changes are seen as a significant increase in the alpha and beta activity, with a reduction in delta activity on an EEG trace.

Missed Dose

Take the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed dose and take the medicine at the next regularly scheduled time. Do not take extra medicine to make up the missed dose.

Storage

Store this medicine at room temperature in a tightly-closed container, away from heat and light.